# FcRH5 expression

Source: https://onco.cc/biomarkers/fcrh5-expression/  
OnCo record `fcrh5-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FcRH5 is a third myeloma surface target after BCMA and GPRC5D. Cevostamab, the FcRH5 x CD3 bispecific, is in phase 3; no approval or threshold exists yet.

## Summary

FcRH5 is expressed on nearly all myeloma cells and gained on 1q21. Cevostamab is being tested in the phase 3 CAMMA 2 trial (NCT05535244) against standard combinations in relapsed or refractory myeloma after BCMA-directed therapy; trials enrol without an FcRH5 expression threshold. No regulator has approved an FcRH5-directed drug.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: FcRH5; FCRL5 expression; FcRH5-positive
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- ClinicalTrials.gov NCT05535244 (CAMMA 2): https://clinicaltrials.gov/study/NCT05535244

## Connected records

- biomarkers: [BCMA expression](https://onco.cc/biomarkers/bcma-expression/), [GPRC5D expression](https://onco.cc/biomarkers/gprc5d-expression/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Cevostamab](https://onco.cc/drugs/cevostamab/)
- targets: [FcRH5 (FCRL5)](https://onco.cc/targets/fcrh5/)

---
JSON: https://onco.cc/api/v1/entities/fcrh5-expression.json